A Phase I/II Study of Clofarabine in Patients with Relapsed T-cell and NK-Cell Lymphomas
[Protocol 06-065]
Full Title :
A PHASE I/II STUDY OF CLOFARABINE IN PATIENTS WITH RELAPSED T-CELL AND NK-CELL LYMPHOMAS
Purpose :
Clofarabine is a drug approved for treating acute lymphoblastic leukemia in children. It works by inhibiting enzymes that cancer cells need to grow and divide. In this study, investigators want to determine if clofarabine is effective against NK-cell or T-cell lymphomas in children and adults.
In the phase I portion of this study, researchers will therefore determine the highest dose of the drug that can be given safely to patients with NK-cell or T-cell lymphomas. In the second part of the study, they will evaluate the drug's effectiveness against these cancers.
Eligibility :
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
Patients must have a confirmed diagnosis of NK-cell or T-cell lymphoma that persists or has returned despite prior therapy.
At least 3 weeks must have passed since completion of previous treatment, and patients must have recovered from any side effects.
Patients must not be confined to a bed or chair for more than half of their normal waking hours.
Patients must be age 2 or older.
For more information and to see if you are eligible for this study, please contact Dr. Steven Horwitz at 212-639-3045.
